Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 192M 166M 155M 142M 267M 18.29B 271M 1.82B 714M 9.15B 720M 704M 30.47B P/E 2026 *
-1.29x
P/E 2027 * -2.01x
Enterprise Value 192M 166M 155M 142M 267M 18.29B 271M 1.82B 714M 9.15B 720M 704M 30.47B EV / Sales 2026 *
4.93x
EV / Sales 2027 * 2.16x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
05:50pm Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
04:36pm Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-22 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-29 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer - 03/12/2024
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+3.90%+7.23%+96.91%+134.11% 1,057B
+0.99%+2.13%+51.05%+51.27% 625B
+0.78%-1.18%+25.21%+64.47% 435B
+1.58%+5.51%+51.42%+40.47% 363B
+0.65%+0.16%+34.81%+39.85% 296B
+0.79%-5.08%+9.78%+7.23% 249B
+1.52%+8.32%+44.75%+60.88% 222B
+0.34%-0.11%-5.23%-51.54% 209B
-0.11%+2.19%+11.43%+65.97% 165B
Average +0.73%+3.10%+35.57%+45.86% 402.31B
Weighted average by Cap. +1.04%+4.76%+51.76%+67.33%

Financials

2026 *2027 *
Net sales 38.94M 33.71M 31.51M 28.79M 54.26M 3.71B 55.11M 369M 145M 1.86B 146M 143M 6.19B 88.93M 76.99M 71.96M 65.77M 124M 8.48B 126M 844M 331M 4.24B 334M 327M 14.13B
Net income -171M -148M -138M -127M -238M -16.32B -242M -1.62B -637M -8.16B -642M -628M -27.19B -156M -135M -126M -115M -217M -14.87B -221M -1.48B -580M -7.44B -585M -573M -24.77B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-